NovoTwist FlexPen

I use pen needles but I haven’t used this new FlexPen.  Actually, if I want to try it, I will have to visit South Africa, Italy, Turkey or Thailand.  It is not yet available in the United States.  It was release last April, and has won the Good Design Award.

 

Here are some questions and answers about the FlexPen from www.novonordisk.com:

• What is different about the NovoTwist® attachment?

NovoTwist® has a unique bayonet attachment that allows you to ‘just twist’ the needle onto Next Generation FlexPen® instead of the ‘turn, turn, turn’ of conventional needles (see ‘Step-by-step guide’).

• Does Next Generation FlexPen® only work with NovoTwist® needles?

No. Next Generation FlexPen® is compatible with NovoTwist®, NovoFine® and all ‘Type A’ compatible needles. It is therefore the only insulin pen that is compatible with such a wide range of needles (see Next Generation FlexPen® homepage for more details).

• Does NovoTwist® have features other than the ‘just twist’ attachment?

Yes. NovoTwist® includes a range of design features to make injections more simple and convenient. Read more about the design of NovoTwist®.

• Why has Novo Nordisk introduced NovoTwist®?

Novo Nordisk is committed to introduce new solutions that can improve the lives of people living with diabetes. In response to input from people with diabetes and healthcare professionals, Novo Nordisk has produced a needle designed specifically to simplify the needle attachment/detachment process for Next Generation FlexPen®. This needle is NovoTwist®.

• Will I benefit from using NovoTwist® instead of needles with the conventional thread attachment?

In surveys of people with diabetes comparing needle types, 7 out of 10 prefer NovoTwist®. NovoTwist® is considered less time-consuming, more user-friendly and simple to use.

University of Texas Research Study

I read this story:  http://www.dallasnews.com/health/

I wanted to name this post Possible Cure for Diabetes but so many articles begin like this.  What makes this study different is that it looks at insulin totally different than we are looking at it today.

“These findings suggest that if there is no glucagon, it doesn’t matter if you don’t have insulin,” said Dr. Unger.

The study will be published in February’s edition of the journal Diabetes.